The entry deadline for this unique learning and development opportunity is 28 January 2016, so don’t delay!
News
Time is running out! Enter International Clinical Researcher of the Year
You’ve only got three weeks left to submit your essay for the International Clinical Researcher of the Year competition for 2016, and with Christmas approaching, time is limited.
UK paying less for cancer drugs than other EU countries
The UK is paying less for new cancer drugs than most other countries in Europe, a new report has found.
Gov’t streams £3m into mental health/schools link pilots
The government is streaming more than £3 million into a new pilot scheme between NHS England and the Department of Education that strives to improve mental health services for children.
Huge demand for diabetes prevention programme
More than three-quarters of Clinical Commissioning Groups in England have now submitted joint expressions of interest in partnership with 132 local authorities to take part in the first phase of the NHS Diabetes Prevention Programme.
Millions use online GP services this year
Online health services in England are booming, with patients on course to use web services offered by GPs to arrange more than 10 million appointments and order more than 15 million prescriptions in this financial year.
NICE turns down Alexion’s £366K-a-year bone disease drug
NHS cost regulators are planning to reject Alexion’s therapy for an ultra-rare bone disorder called paediatric-onset hypophosphatasia, which affects just seven people a year in England.
NICE u-turn on Novartis’ multiple myeloma drug
The National Institute for Health and Care Excellence is now recommending Novartis’ Farydak as a third-line treatment for patients with multiple myeloma after initially rejecting the drug for NHS use earlier this year.
Novo’s Victoza beats SGLT2 inhibitors in lowering blood sugar
New data show that treatment with Novo Nordisk’s Victoza provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose co-transporter 2 inhibitors in people with type II diabetes unable to hit targets with other treatments.
Second patient dies in obesity drug trial
A second patient has died while taking part in a late-stage trial assessing an anti-obesity drug being developed by US biotech Zafgen for the genetic disorder Prader-Willi syndrome.
Stroke services need improving, finds UK audit
The latest national audit of stroke services in the UK has revealed some progress in the care of patients, but also highlights key areas where more work needs to be done to ensure access to interventions and appropriate hospital assessments.
Boehringer ties with US cancer centre in discovery deal
Boehringer Ingelheim has linked with US cancer research and care institute the MD Anderson Cancer Center in a deal focused on the development of novel approaches to treating pancreatic cancer, extending its focus on difficult-to-treat diseases.
EU OK for GSK’s novel asthma biologic
Hot on the heels of its US approval GlaxoSmithKline’s asthma biologic Nucala has now also bagged clearance in the EU for a difficult-to-treat form of asthma.
Gilead in hot water over Sovaldi pricing in US
The worldwide controversy over the pricing of Gilead’s hepatitis C drug Sovaldi has ramped up with a US Senate Finance Committee investigation concluding that the company put profit ahead of patients.
NICE advocates tailored approach to treating diabetes
NICE has finally published a long-awaited update to its guideline on the treatment and management of type II diabetes, with a new focus on an individualised approach to secure the best outcomes for patients.
